NurExone Biologic Inc. (NRX.V)

0.5900 -0.0100 (-1.67%) At close: 03:36PM EDT

NurExone Biologic Inc.

1 First Canadian Place
Suite 1600 100 King Street West
Toronto, ON M5X 1G5
Canada

https://nurexone.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Yoram Drucker	Co-Founder, VP of Strategic Development & Chairman	196.17k	N/A	1965
Dr. Lior Shaltiel	CEO & Director	404.39k	N/A	N/A
Mr. Eran Ovadya M.B.A.	CFO & Secretary	402.54k	N/A	N/A
Mr. Gabriel Eldor	Co-Founder & Business Development Manager	N/A	N/A	N/A
Dr. Ina Sarel Ph.D.	Head of CMC, Quality & Regulation	N/A	N/A	N/A
Mr. Nirit Drori-Carmi	Head of Bioprocess Development	N/A	N/A	N/A

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.

Description

NurExone Biologic Inc., a pharmaceutical technology company. It engages in the development of an off-the-shelf, non-invasive, and novel treatment for the reversal or reduction of paralysis following spinal cord injury using membrane-bound extracellular vesicles technology, as well as to treat brain trauma injury, and other brain and neurological indications. The company was founded in 2020 and is based in Toronto, Canada.

Corporate Governance

NurExone Biologic Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.